Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of (R)-Indoprofen. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 4/20 | 1.00 |
| ▸ | RAB9A | P51151 | 4/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 1.00 |
| ▸ | PKM | P14618 | 3/20 | 1.00 |
| ▸ | TP53 | P04637 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | PGR | P06401 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | GAA | P10253 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | DRD1 | P21728 | 1/20 | 1.00 |
| ▸ | HTT | P42858 | 1/20 | 1.00 |
| ▸ | NFKB2 | Q00653 | 1/20 | 1.00 |
| ▸ | RELA | Q04206 | 1/20 | 1.00 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dexindoprofen SCHEMBL286896 | 1.00 | NPC1 (1.00) | NPC1RAB9ASMN1; SMN2PKMTP53 | |
| (R)-Indoprofen SCHEMBL30910963 | 1.00 | NPC1 (1.00) | NPC1RAB9ASMN1; SMN2PKMTP53 | |
| Indoprofen SCHEMBL10600175 | 1.00 | NPC1 (1.00) | NPC1RAB9ASMN1; SMN2PKMTP53 | |
| Indoprofen SCHEMBL29361927 | 1.00 | NPC1 (1.00) | NPC1RAB9ASMN1; SMN2PKMTP53 | |
| (R)-Indoprofen SCHEMBL30910962 | 1.00 | NPC1 (1.00) | NPC1RAB9ASMN1; SMN2PKMTP53 | |
| Indoprofen SCHEMBL25137 | 1.00 | NPC1 (1.00) | NPC1RAB9ASMN1; SMN2PKMTP53 | |
| Indoprofen SCHEMBL10850545 | 0.99 | NPC1 (0.97) | NPC1RAB9ASMN1; SMN2PKMTP53 | |
| SCHEMBL10115277 | 0.92 | NPC1 (0.85) | NPC1RAB9ASMN1; SMN2PKMTP53 | |
| SCHEMBL15695571 | 0.92 | NPC1 (0.85) | NPC1RAB9ASMN1; SMN2PKMTP53 | |
| SCHEMBL11550044 | 0.90 | NPC1 (0.81) | NPC1RAB9ASMN1; SMN2PKMTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1196622-B1 | THE USE OF ORTHOESTERS FOR THE SYNTHESIS OF CHIRAL ACIDS IN BIOCATALYZED IRREVERSIBLE ESTERIFICATION PROCESSES | CONSIGLIO NAZIONALE RICERCHE (IT) | 2005-05-18 | — | — | EP | claimed |
| US-20120083495-A1 | COMPOUNDS FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY AND OTHER USES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, | 2012-04-05 | — | — | US | disclosed |
| US-8110681-B2 | Compounds for the treatment of spinal muscular atrophy and other uses | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2012-02-07 | — | — | US | disclosed |
| US-8110681-B2 | Compounds for the treatment of spinal muscular atrophy and other uses | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2012-02-07 | — | — | US | disclosed |
| US-20090312323-A1 | COMPOUNDS FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY AND OTHER USES | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HHS (US) | 2009-12-17 | — | — | US | disclosed |
| US-20070232589-A1 | Pharmaceutical Composition And Method For Treating Neurodegenerative Disorders | MYRIAD GENETICS, INCORPORATED (US) | 2007-10-04 | — | — | US | disclosed |
| US-20070232656-A1 | Pharmaceutical Composition And Method For Treating Neurodegenerative Disorders | MYRIAD GENETICS, INCORPORATED (US) | 2007-10-04 | — | — | US | disclosed |
| US-20070232672-A1 | Pharmaceutical Composition And Method For Treating Neurodegenerative Disorders | MYRIAD GENETICS, INCORPORATED (US) | 2007-10-04 | — | — | US | disclosed |
| WO-2006020850-A2 | PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING NEURODEGENERATIVE DISORDERS | MYRIAD GENETICS, INC. (US) | 2006-02-23 | — | — | WO | disclosed |
| WO-2006020852-A2 | PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING NEURODEGENERATIVE DISORDERS | MYRIAD GENETICS, INC. (US) | 2006-02-23 | — | — | WO | disclosed |
| WO-2006020853-A2 | PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING NEURODEGENERATIVE DISORDERS | MYRIAD GENETICS, INC. (US) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232672-A1 | Pharmaceutical Composition And Method For Treating Neurodegenerative Disorders | ACHE, BCHE, CHAT | PTGS2 2810/4885NPC1 91/4885RAB9A 2532/4885 |
| US-20070232589-A1 | Pharmaceutical Composition And Method For Treating Neurodegenerative Disorders | ACHE, BCHE, CHAT | PTGS2 2842/4885NPC1 95/4885RAB9A 2552/4885 |
| US-20120083495-A1 | COMPOUNDS FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY AND OTHER USES | SMN1; SMN2, RNMT, CPT1B | PTGS2 3025/4885NPC1 1076/4885RAB9A 1487/4885 |
| US-20090312323-A1 | COMPOUNDS FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY AND OTHER USES | SMN1; SMN2, RNMT, CPT1B | PTGS2 2547/4885NPC1 1202/4885RAB9A 1591/4885 |
| US-20070232656-A1 | Pharmaceutical Composition And Method For Treating Neurodegenerative Disorders | ACHE, BCHE, CHAT | PTGS2 2810/4885NPC1 91/4885RAB9A 2532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.